Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Nucific vs Voxy

Nucific
Graded #417

Lower grade

vs+6.199999999999996
Voxy
Graded #272

Higher grade

The verdict

Voxy takes it — 62.4/100 to 56.2/100.

Voxy grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Voxy is a Scottsdale, Arizona telehealth practice offering compounded semaglutide and tirzepatide alongside NAD+ and sermorelin.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVoxy +6
45
51
Dose & formulationVoxy +11
53
64
Clinical oversightVoxy +6
76
82
Labs & monitoringVoxy +11
52
63
FulfillmentVoxy +11
67
78
Contract termsNucific +21
41
20
Nucific · left barVoxy · right bar

The numbers

MetricNucificVoxy
WeighScore56.2/10062.4/100
GradeCC
Scorecard rank#417#272
SemaglutideNot disclosed$179/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Nucific

Graded #417 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials
Voxy

Graded #272 · C

Strengths

  • Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
  • Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
  • One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
  • True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
  • Free assessment with no charge to see if you qualify, and no labs required to start

Where it loses points

  • No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
  • No refund policy published; the only stated commitment language is 'cancel anytime'
  • Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
  • No public list of states served; availability depends on where affiliated providers are licensed
  • The prescribing nurse practitioner is not named — 'provider details available during your consultation'

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard